3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Hodgkin Disease
2
Glioblastoma
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemoglobinuria, Paroxysmal
1
Gliosarcoma
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Aplastic
1
Interventions
Temozolomide
203
Radiotherapy
118
Bevacizumab
93
Radiation
40
Magnetic Resonance Spectroscopy
28
Irinotecan
27
Carmustine
25
Surgical Procedures, Operative
24
Lomustine
21
Erlotinib Hydrochloride
19
Chemotherapy, Adjuvant
18
Carboplatin
17
temsirolimus
13
Drug Therapy
13
O(6)-benzylguanine
12
Nivolumab
12
sargramostim
11
Sirolimus
11
Radiotherapy, Intensity-Modulated
11
Radiotherapy, Conformal
11
Sorafenib
10
Radiosurgery
10
Imatinib Mesylate
10
Everolimus
10
pembrolizumab
9
motexafin gadolinium
9
Vorinostat
9
Thalidomide
8
IL13-PE38
8
Gefitinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Glioblastoma
×
Basiliximab
×
Clear all
NCT02366728
2023-06-08
ELEVATE
Duke University
Phase 2
Completed
64 enrolled
17 charts
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled